CERo Net Debt To E B I T D A from 2010 to 2025
| CEROW Stock | 0.01 0 18.30% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (0.54) | Current Value (0.51) | Quarterly Volatility 152.8211837 |
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
CERo | Net Debt To E B I T D A |
Latest CERo Therapeutics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of CERo Therapeutics Holdings over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). CERo Therapeutics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
CERo Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 32.06 | |
| Coefficient Of Variation | 476.72 | |
| Mean Deviation | 71.62 | |
| Median | (7.54) | |
| Standard Deviation | 152.82 | |
| Sample Variance | 23,354 | |
| Range | 613 | |
| R-Value | 0.27 | |
| Mean Square Error | 23,264 | |
| R-Squared | 0.07 | |
| Significance | 0.32 | |
| Slope | 8.51 | |
| Total Sum of Squares | 350,315 |
CERo Net Debt To E B I T D A History
About CERo Therapeutics Financial Statements
CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | (0.54) | (0.51) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.